Comment
doi: 10.1056/NEJMc1907520.
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Affiliations
- PMID: 31314981
- DOI: 10.1056/NEJMc1907520
Item in Clipboard
Comment
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
N Engl J Med.
.
No abstract available
Comment in
-
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply.N Engl J Med. 2019 Jul 18;381(3):e6. doi: 10.1056/NEJMc1907520. N Engl J Med. 2019. PMID: 31314982 No abstract available.
Comment on
-
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
Similar articles
-
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply.N Engl J Med. 2019 Jul 18;381(3):e6. doi: 10.1056/NEJMc1907520. N Engl J Med. 2019. PMID: 31314982 No abstract available.
-
Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.Biomed Pharmacother. 2023 Dec;168:115691. doi: 10.1016/j.biopha.2023.115691. Epub 2023 Oct 14. Biomed Pharmacother. 2023. PMID: 37844355
-
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001. Hum Gene Ther. 2018. PMID: 29641319 Free PMC article.
-
[CAR-T cells immunotherapy in multiple myeloma: Present and future].Bull Cancer. 2021 Oct;108(10S):S65-S72. doi: 10.1016/j.bulcan.2021.09.005. Bull Cancer. 2021. PMID: 34920809 Review. French.
-
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17. Scand J Immunol. 2020. PMID: 32471019 Review.
Cited by
-
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment.Front Oncol. 2020 Aug 5;10:1362. doi: 10.3389/fonc.2020.01362. eCollection 2020. Front Oncol. 2020. PMID: 32850436 Free PMC article. Review.
-
Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity.Cell Rep Med. 2024 May 21;5(5):101530. doi: 10.1016/j.xcrm.2024.101530. Epub 2024 Apr 29. Cell Rep Med. 2024. PMID: 38688275 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
